Last updated: May 25, 2026
Suppliers for the Pharmaceutical Drug Selinexor: API, Drug-Product, and Key Supply-Chain Risks
Selinexor supply in the commercial market depends on a small number of qualified manufacturers for the active pharmaceutical ingredient (API) and finished drug product (capsules). For a defensible supplier map, the controlling data are the Drug Master File (DMF) holders and the FDA-approved manufacturing sites listed in the Orange Book and labeling for the marketed product (Xpovio, exelinexor). Without those FDA-verified listings for the specific dosage forms and label strength (and without the associated DMF/Orange Book patent-manufacturing tables), a complete and accurate supplier list cannot be produced.
What company supplies selinexor API (active ingredient) for Xpovio?
Key answer: API supplier identification must be grounded in FDA Orange Book manufacturing-site and/or DMF references tied to Xpovio (selinexor/exelinexor) dosage forms and strengths. An API supplier list based on third-party catalogs alone is not reliable for procurement, licensing, or litigation due diligence.
Which API manufacturing sites are typically tied to FDA approvals?
For a precision supplier map, the relevant fields are:
- Orange Book “Applicant/Manufacturer” and listed manufacturing locations for Xpovio
- DMF referenced under the application for selinexor drug substance
How do API supplier changes show up in regulatory records?
Supply transitions usually appear as:
- Changes to manufacturing sites in annual reports (e.g., site additions/variations)
- Type II variations for manufacturing process or equipment
- New or amended DMFs for drug substance
Who manufactures the selinexor finished capsules (drug product) and packaging?
Key answer: finished-dose manufacturers must be pulled from the FDA-approved product labeling and Orange Book listing for the specific capsule strengths and dosage form. “Finished product supplier” is not the same as “packager,” and packaging site changes can occur independently.
What to check in Xpovio labeling for procurement-grade supplier mapping?
- Holders and manufacturers listed for “manufactured for” and “distributed by”
- Storage conditions and strength-specific presentations that map to manufacturing lots
How packaging suppliers affect availability?
- Serialization/labeling vendors and packaging sites can constrain launch or continuity even if API supply is stable
- Labeling supply disruptions can delay release of otherwise manufactured batches
What are the Orange Book listings for Xpovio that identify manufacturers?
Key answer: Orange Book listings identify the approved application and the “applicant” plus manufacturing site(s) for drug products and, in some cases, drug substance details via referenced DMFs.
How to use Orange Book data for supplier selection
Procurement-grade due diligence typically requires:
- Crosswalk of Orange Book manufacturing locations to GMP inspection history
- Confirmation that the manufacturing site corresponds to the exact dosage form (capsule) and strength
Are there contract manufacturers supplying selinexor for other brands or authorized generics?
Key answer: any contract-manufacturing relationship for selinexor outside Xpovio depends on whether another approved application exists for the same active ingredient and dosage form. Supplier lists must be tied to FDA approvals for each presentation.
What counts as a qualifying “supplier” for licensing and litigation?
- FDA-approved manufacturer of record for the specific product
- Authorized contract manufacturer listed in the application submissions
How many suppliers exist for selinexor, and what is the concentration risk?
Key answer: the number of qualified manufacturers for selinexor is typically limited by:
- niche synthetic route complexity
- containment and potency handling requirements
- validated commercial process scale and regulatory history
But supplier concentration cannot be quantified without the FDA-verified list of manufacturing sites for the drug product and drug substance.
What happens to selinexor supply if there is an API shortage?
Key answer: practical continuity depends on whether alternative API suppliers are qualified in the DMF and can be transferred to drug product manufacturing with approved regulatory changes.
Common supply-chain breakpoints in niche oncology APIs
- DMF holder capacity constraints for drug substance
- Release testing bottlenecks for finished lots
- Regulatory variation timelines for process or site transitions
What supplier audits and GMP checks matter for selinexor?
Key answer: GMP qualification for oncology APIs and cytotoxic-adjacent compounds focuses on:
- aseptic versus non-aseptic controls (selinexor capsules are typically non-sterile, but the validated process controls still govern quality)
- cleaning validation and cross-contamination control
- analytical method validation and stability program coverage
What documentation is typically required for procurement?
- CoC/CoA with complete batch record traceability
- GMP certificates for the manufacturing sites
- Change control history affecting the last 12 to 24 months of supply
How does selinexor supplier qualification differ from biosimilars or biologics?
Key answer: selinexor is a small-molecule, so supplier qualification is based on chemistry, manufacturing, and controls (CMC) rather than biologic comparability and reference product bridging.
What this means for second-source API strategy
- Analytical comparability (assay, impurities, polymorph control if relevant)
- Solid-state form controls and impurity specification alignment
- Process validation and impurity profile consistency
Key Takeaways
- A complete, procurement-accurate supplier list for selinexor requires FDA-verified manufacturer-of-record and DMF/Orange Book references tied to Xpovio capsules and the specific strengths.
- Finished product and API supply are governed by different regulatory records, so “supplier” must be mapped by dosage form and manufacturing site.
- Concentration and shortage risk is a function of qualified capacity across drug substance and drug product sites; quantification requires the Orange Book and labeling manufacturing-site tables.
FAQs
Which FDA document lists selinexor (Xpovio) manufacturers for each capsule strength?
The FDA Orange Book listing and Xpovio prescribing information manufacturer sections are the controlling references.
Can I rely on online chemical catalogs to identify selinexor API suppliers?
No. procurement-grade identification must be tied to FDA DMFs and Orange Book manufacturing-site listings.
What is the difference between an API DMF supplier and a drug product manufacturer?
A DMF holder supplies the drug substance used in the approved drug product process; the drug product manufacturer releases finished lots under the NDA/approved application.
Are there multiple packaging sites for Xpovio?
Packaging and labeling sites can differ from bulk manufacturing sites and may change via regulatory variations, so the packaging site must be confirmed from FDA labeling and site listings.
How do supplier changes get reflected in regulatory status?
They typically appear through manufacturing site updates in regulatory submissions and corresponding Orange Book/labeling updates for the affected strengths and dosage forms.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- FDA. Xpovio (selinexor) Prescribing Information (accessed via FDA labeling database). https://www.accessdata.fda.gov/scripts/cder/daf/
